NasdaqGS:CMPSBiotechs
Could COMPASS Pathways’ (CMPS) Low-Touch Psilocybin Protocol Quietly Redefine Its Competitive Edge in PTSD?
Earlier this month, COMPASS Pathways plc reported a post-hoc analysis from an open-label Phase 2 study of its investigational COMP360 synthetic psilocybin treatment in PTSD, showing that administration sessions were characterized by minimal, largely non-directive support with about four-fifths of session time spent in silence.
The analysis highlights that carefully structured, low-intervention support and a standardized training program for support providers may be central to fostering...